Table 6 Factors associated with biochemical recurrence in entire cohort and each risk group

HR

95%CI

p-value

HR

95%CI

p-value

PSAD >0.345 vs ≤0.345 ng/ml/

3.105

1.669–5.776

<0.001

% positive cores >21.4 vs ≤21.4%

2.490

1.363–4.551

0.003

% dominant side >37.5 vs ≤37.5%

3.793

2.016–7.136

<0.001

2.648

1.369–5.121

0.004

% cancer extent >55.6 vs ≤55.6%

3.301

1.778–6.130

<0.001

2.505

1.324–4.741

0.005

NCCN risk high vs intermediate

2.517

1.391–4.555

0.002

2.069

1.129–3.791

0.019

HR

95%CI

p-value

HR

95%CI

p-value

PSAD >0.190 vs ≤0.190 ng/ml/cc

2.040

0.803–5.185

0.134

% positive cores >21.4 vs ≤21.4%

3.910

1.485–10.29

0.006

3.910

1.485–10.29

0.006

% dominant side >36.4 vs ≤36.4%

1.111

0.871–1.418

0.398

% cancer extent >57.1 vs ≤57.1%

3.207

1.288–7.984

0.012

HR

95%CI

p-value

HR

95%CI

p-value

PSAD >0.345 vs ≤0.345 ng/ml/cc

3.121

1.428–6.824

0.004

3.103

1.373–7.012

0.006

% positive cores >35.0 vs ≤35.0%

3.005

1.374–6.572

0.006

% dominant side >40.0 vs ≤40.0

2.404

1.089–5.306

0.030

% cancer extent >55.6 vs ≤55.6%

2.788

1.218–6.382

0.015